B Cell Subset Analysis
Also known as: B SUBSETS
Use
This panel identifies B-cell dysregulation, aids in diagnosing common variable immunodeficiency (CVID), and assists in predicting clinical phenotypes. It can assess B cell reconstitution post-bone marrow or hematopoietic stem cell transplantation. It is effective in identifying disorders impacting CD27+ B-cells and immunoglobulin class switching, crucial for mature B-cell development and function.
Special Instructions
Not recommended for rituximab monitoring; refer to B-cell CD20 Expression (0092099). Specimens must be transported refrigerated and analyzed within 48 hours of collection.
Limitations
Reference intervals for CD20+ B-cells are not established for patients under 16. Other B-cell subsets' intervals for patients younger than 16 are literature-derived. The test is unsuitable for monitoring rituximab therapy and has specific limitations for interpreting CD20+ subsets in younger populations.
New York Approved
Methodology
Cell-based / Cytometry (Flow Cytometry)
Biomarkers
LOINC Codes
- 9558-8
- 94689-7
- 94755-6
- 94754-9
- 89343-8
- 89344-6
- 8116-6
- 8117-4
- 89351-1
- 89352-9
- 89349-5
- 89350-3
- 89353-7
- 89358-6
- 89357-8
- 89341-2
Result Turnaround Time
1-3 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
4 mL
Minimum Volume
2 mL
Container
Lavender (K2EDTA) or Pink (K2EDTA) tube
Storage Instructions
Transport specimens refrigerated
Causes for Rejection
Clotted or hemolyzed specimens.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | Unacceptable |
| Refrigerated | 48 hours |
| Frozen | Unacceptable |